Japanese pair join trial of Opdivo combo

22 August 2018

A Phase III trial is to start testing the combination of the PD1 immune checkpoint inhibitor Opdivo (nivolumab) and the tyrosine kinase inhibitor Cabometyx (cabozantinib) in Japan, extending a study going on elsewhere.

Japanese drugmakers Ono Pharmaceutical (TYO: 4528) and Takeda (TYO: 4502) are to collaborate in the trial to test the combination’s efficacy and safety as a potential treatment for Cabometyx (cabozantinib) renal cell carcinoma (RCC) in Japan.

They will join a trial that has been going on outside Japan under a collaboration involving Bristol-Myers Squibb (NYSE: BM), the US pharma major that holds rights to Opdivo outside Japan, South Korea and Taiwan, and French drugmaker Ipsen (Euronext: IPN), the rights holder for Cabometyx outside Japan and the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK